Sumitomo Group

2020 Agrochemicals Market Analysis: Fungicides, Herbicides, Insecticides - Global Trends, Competitive Landscape, and Opportunities for Suppliers - ResearchAndMarkets.com

Friday, May 29, 2020 - 2:09pm

The companies analyzed in this report include ADAMA, BASF, Bayer, Corteva, FMC, Nufarm, Sumitomo, Syngenta, and UPL Limited.

Key Points: 

The companies analyzed in this report include ADAMA, BASF, Bayer, Corteva, FMC, Nufarm, Sumitomo, Syngenta, and UPL Limited.
Specific business, new product development and marketing strategies.

Resorcinol Market Forecasts to 2025 by Value and Volume

Wednesday, May 27, 2020 - 11:30am

The Global Resorcinol Market is projected to grow at a steady CAGR during the forecast period.

Key Points: 
  • The Global Resorcinol Market is projected to grow at a steady CAGR during the forecast period.
  • Moreover, resorcinol is also used to manufacture flame retardants to prevent fires, fungicidal creams & lotions, etc., thereby bolstering the market growth until 2025.
  • The Global Resorcinol Market is segmented based on end-user industry, manufacturing process, application, region and company.
  • Major players operating in the Global Resorcinol Market include Sumitomo Chemicals, Aldon Corporation, AminoChem, Dynea, Mitsui Chemicals, Napp Technologies, Zhejiang Hongsheng Chemical Co Ltd, Indspec Chemical, Atul Ltd and others.

Urovant Sciences to Present at the Jefferies Virtual Healthcare Conference

Tuesday, May 26, 2020 - 1:00pm

Urovant Sciences (Nasdaq: UROV) announced today that President and Chief Executive Officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, June 2, 2020, at the Jefferies Healthcare Conference, which is being held virtually.

Key Points: 
  • Urovant Sciences (Nasdaq: UROV) announced today that President and Chief Executive Officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, June 2, 2020, at the Jefferies Healthcare Conference, which is being held virtually.
  • Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.
  • Urovant Sciences reported positive data from the vibegron 12-week, Phase 3 pivotal EMPOWUR study and demonstrated favorable longer-term efficacy, safety, and tolerability in a 40-week extension study.
  • Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., which is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., intends to develop novel treatments for additional urologic diseases.

OEC to Provide Mazda with RepairLink for Mechanical Parts Marketing Program

Tuesday, May 26, 2020 - 12:00pm

CLEVELAND, May 26, 2020 /PRNewswire-PRWeb/ --OEConnection LLC (OEC), the leading automotive technology provider for original equipment manufacturers' (OEM) distribution networks, will provide Mazda North American Operations (Mazda) with RepairLink, the market-leading mechanical parts sourcing technology.

Key Points: 
  • CLEVELAND, May 26, 2020 /PRNewswire-PRWeb/ --OEConnection LLC (OEC), the leading automotive technology provider for original equipment manufacturers' (OEM) distribution networks, will provide Mazda North American Operations (Mazda) with RepairLink, the market-leading mechanical parts sourcing technology.
  • Mazda is the 10th OEM to adopt RepairLink to facilitate their online OEM parts marketing program, with RepairLink programs covering over 80 percent of US vehicles.
  • RepairLink also provides dealers with the opportunity to offer promotional pricing on popular parts through the Parts Marketing Program (PMA), and online access to part ordering and fulfillment.
  • "Typically, RepairLink dealers participating in an OEM parts marketing program see a nearly 60 percent increase in part sales, and OEC anticipates Mazda experiencing similar success in the market."

Poxel Successfully Raises €17.7 Million in a Capital Increase

Monday, May 25, 2020 - 7:00am

This press release does not constitute a prospectus within the meaning of the Prospectus Directive nor a public offering.

Key Points: 
  • This press release does not constitute a prospectus within the meaning of the Prospectus Directive nor a public offering.
  • In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities.
  • Together, with its partner Sumitomo Dainippon Pharma, Poxel successfully completed the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Tokyo Metropolitan Government to trial 5G Antenna-equipped Smart Poles in Cooperation with Sumitomo Corporation and NEC

Monday, May 25, 2020 - 2:44am

TOKYO, May 25, 2020 - (JCN Newswire) - Sumitomo Corporation has concluded an agreement with the Tokyo Metropolitan Government on the preliminary/trial installation and verification of smart poles being carried out by the government.

Key Points: 
  • TOKYO, May 25, 2020 - (JCN Newswire) - Sumitomo Corporation has concluded an agreement with the Tokyo Metropolitan Government on the preliminary/trial installation and verification of smart poles being carried out by the government.
  • Together with NEC Corporation, Sumitomo Corporation intends to install two types of smart poles in the Nishi-shinjuku area of Tokyo by the end of June 2020.
  • In its "TOKYO Data Highway Basic Strategy" formulated in August 2019, the Tokyo Metropolitan Government calls for constructing an ultra-high-speed mobile Internet network in Tokyo.
  • In partnering with the Tokyo Metropolitan Government, Sumitomo Corporation and NEC will be installing two types of smart poles in the Nishi-shinjuku area by the end of June 2020 to verify their utility under both ordinary and emergency circumstances.

Mazda Production and Sales Results for March 2020 and for April 2019 through March 2020

Tuesday, April 28, 2020 - 10:21am

TOKYO, Apr 28, 2020 - (JCN Newswire) - Mazda Motor Corporation's production and sales results for March 2020 and for April 2019 through March 2020 are summarized below.

Key Points: 
  • TOKYO, Apr 28, 2020 - (JCN Newswire) - Mazda Motor Corporation's production and sales results for March 2020 and for April 2019 through March 2020 are summarized below.
  • Mazda's domestic production volume in March 2020 decreased 17.6% year on year due to decreased production of passenger vehicles.
  • Mazda's domestic production volume in the period from April 2019 through March 2020 decreased 3.8% year on year due to decreased production of passenger and commercial vehicles.
  • Mazda's overseas production volume in March 2020 decreased 24.8% year on year due to decreased production of passenger and commercial vehicles.

Mazda Releases FY March 2020 Full Year Financial Results

Thursday, May 14, 2020 - 9:01am

TOKYO, May 14, 2020 - (JCN Newswire) - Mazda announced its medium-term management plan in November last year.

Key Points: 
  • TOKYO, May 14, 2020 - (JCN Newswire) - Mazda announced its medium-term management plan in November last year.
  • The automobile industry is experiencing the kind of transformation which takes place only once in 100 years.
  • Mazda Motor Corporation (TSE: 7261) started manufacturing tools in 1929 and soon branched out into production of trucks for commercial use.
  • In the early 1960s, Mazda launched its first passenger car models and began developing rotary engines.

Sunovion Discontinues Dasotraline Program

Wednesday, May 13, 2020 - 1:03pm

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has withdrawn the New Drug Applications (NDAs) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of moderate-to-severe binge eating disorder (BED) and attention deficit hyperactivity disorder (ADHD).

Key Points: 
  • Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has withdrawn the New Drug Applications (NDAs) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of moderate-to-severe binge eating disorder (BED) and attention deficit hyperactivity disorder (ADHD).
  • While Sunovion considers dasotraline to be a promising, novel treatment for BED and ADHD, we believe that further clinical studies would be needed to support a regulatory approval for dasotraline in these indications.
  • Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the companys websites: www.sunovion.com , www.sunovion.eu and www.sunovion.ca .
  • Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
    2020 Sunovion Pharmaceuticals Inc. All rights reserved.

Sumitomo Chemical Innovates with Anaqua’s AQX IP Management Platform

Tuesday, May 12, 2020 - 3:18pm

Boston, May 12, 2020 (GLOBE NEWSWIRE) -- Anaqua , the leading provider of innovation and intellectual property management solutions, today announced that Japanese multinational company Sumitomo Chemical will enhance its IP management system by moving to Anaquas AQX platform.

Key Points: 
  • Boston, May 12, 2020 (GLOBE NEWSWIRE) -- Anaqua , the leading provider of innovation and intellectual property management solutions, today announced that Japanese multinational company Sumitomo Chemical will enhance its IP management system by moving to Anaquas AQX platform.
  • Sumitomo Chemical, a manufacturer in petrochemicals, organic chemicals, IT-related chemicals, agrochemicals, and pharmaceuticals, opted for Anaqua when replacing its previous IP management system.
  • The company will leverage Anaquas latest version of AQX software to streamline the entire IP management lifecycle from innovation creation and disclosure to patent annuity payment services.
  • Sumitomo Chemical has established itself as one of the most innovative companies in its field, and AQX will help IP portfolio managers at Sumitomo Chemical ensure they maximize the value of the organizations IP assets.